Circulating soluble tumor necrosis factor receptors, interleukin‐2 receptors, tumor necrosis factor α, and interleukin‐6 levels in rheumatoid arthritis.

Arthritis & Rheumatism

Volumn 36, Issue 8, 1993, Pages 1070-1079

  Barrera, Pilar ^a,b,c   Th Boerbooms, Agnes M ^a,b,c   Janssen, Elly M ^a,b,c   Sauerwein, Robert W ^a,b,c   Gallati, H ^a,b,c   Mulder, Jan ^a,b,c   Boo, Theo De ^a,b,c   Demacker, Pierre N M ^a,b,c   Van De Putte, Levinus B A ^a,b,c   Van Der Meer, JOS W M ^a,b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; SEROLOGY;

ARTHRITIS, RHEUMATOID; AZATHIOPRINE; COMPARATIVE STUDY; CYTOKINES; DOUBLE-BLIND METHOD; HUMAN; INTERLEUKIN-6; LONGITUDINAL STUDIES; METHOTREXATE; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR;

EID: 0027201923     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780360807     Document Type: Article

References (45)

1. Analysis of IL1 and TNF‐α gene expression in human rheumatoid synoviocytes by in situ hybridization
2. Immunoassay, bioassay and in situ hybridization of monokines in human arthritis
3. Interleukin‐1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL‐1α
4. Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis
5. Interleukin‐6 localisation in the synovial membrane in rheumatoid arthritis
6. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
7. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts
8. In situ hybridization of IL‐6 in rheumatoid arthritis
9. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
10. Cytokine production in the arthritis joint: implications for treatment
11. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro
12. The soluble interleukin‐2 receptor: biology, function and clinical application
13. Two tumor necrosis factor‐binding proteins purified from human urine: evidence for immunological cross‐reactivity with cell surface tumor necrosis factor receptors
14. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
15. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
16. Interleukin 6 (IL‐6) in synovial fluid and serum of patients with rheumatic diseases
17. Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
18. Interleukin‐6 in synovial fluid from patients with arthritis
19. Elevated soluble interleukin‐2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis
20. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases (abstract)
21. Franssen MJAM, de Rooy D‐JRAM: Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty‐eight–week, randomized, double‐blind trial
22. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double‐blind study
23. Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro
24. Functional discrimination between interleukin 6 and interleukin 1
25. A distribution‐free test for tumor‐growth curve analysis with application to an animal tumor immunotherapy experiment
26. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score
27. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis
28. Serum levels of interleukin‐2 receptor and activity of rheumatic diseases characterized by immune system activation
29. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity
30. Serum interleukin‐2 receptor in rheumatoid arthritis: a prognostic indicator of disease activity?
31. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease
32. Serum tumor necrosis factor levels in patients with infectious disease and septic shock
33. Increased levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation
34. Detection of tumor necrosis α but not tumor necrosis factor b̃ in rheumatoid arthritis synovial fluid and serum
35. Tumor necrosis factor in serum and synovial fluid of patients with active and severe RA
36. Tumor necrosis factor alpha and interleukin‐2 in plasma from rheumatoid arthritis patients in relation with disease activity
37. Evidence of different effects of soluble TNF‐receptors on various TNF measurements in human biological fluids
38. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo
39. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage–pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α
40. What's new about tumor necrosis factors? Report on the fourth TNF international congress
41. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia
42. New immunological measures of disease activity in rheumatoid arthritis: interleukin 6 and soluble interleukin 2 receptor levels in a 6 month trial (abstract)
43. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis
44. The effect of second line drugs on serum interleukin 6 levels in rheumatoid arthritis (abstract)
45. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine